Researchers at Baylor College of Medicine have discovered that combining the PARP inhibitor olaparib with the ATR inhibitor ceralasertib significantly reduces tumor growth in triple-negative breast cancers (TNBC) lacking the DNA ligase I (LIG1) gene. According to a study published in Molecular Cancer Therapeutics, LIG1 loss in TP53-mutant tumors creates a specific vulnerability that makes these chemotherapy-resistant cells susceptible to this dual-drug combination.
LIG1 Loss as a Biomarker for Platinum Resistance
Triple-negative breast cancer is notoriously difficult to treat. Dr. Meenakshi Anurag, assistant professor of medicine at Baylor, stated that her team’s proteogenomic profiling revealed that the loss of one copy of the LIG1 gene is robustly associated with resistance to chemotherapy, particularly platinum agents, in TNBCs with TP53 mutations.
When LIG1 is missing, the cancer cells rewire their DNA repair mechanisms to survive. While this allows the tumor to ignore standard chemotherapy, it creates a “therapeutic Achilles’ heel.” By identifying LIG1 status before treatment, clinicians can potentially stratify patients to determine who will fail standard platinum therapy and who might benefit from targeted combinations.
Did you know? Triple-negative breast cancer (TNBC) is a type of breast cancer.
The Synergy of Olaparib and Ceralasertib
The research team initially tested FDA-approved PARP inhibitors, which block enzymes that repair damaged DNA. However, first author Anh M. Tran-Huynh noted that PARP inhibitors alone showed only modest activity in LIG1-loss models. To find a more potent solution, Baylor collaborated with Dr. Christopher Lord and Dr. Andrew Tutt at the Institute of Cancer Research in London.
The collaboration involved screening PARP inhibitors against 120 different DNA damage response inhibitors. The results showed that combining olaparib (a PARP inhibitor) with ceralasertib (an ATR inhibitor) was significantly more effective than using either drug as a monotherapy in both TP53-mutant/LIG1-loss cell lines and animal models.
Dr. Matthew Ellis, co-corresponding author and visiting professor at the State University of Campinas, compared this discovery to the success of PARP inhibitors in BRCA1- and BRCA2-deficient tumors. He noted that the mechanistic approach—identifying a specific genetic deficiency like LIG1 loss—is critical for developing effective combination therapies.
Future Trends in Precision Oncology for TNBC
The use of LIG1 as a predictive biomarker could lead to the following trends in clinical practice:
- Patient Stratification: Using LIG1 levels to identify high-risk patients who are likely to resist platinum-based chemotherapy.
- Combination Screening: Moving beyond single-drug targets to pairs, such as ATR and PARP inhibitors.
Frequently Asked Questions
What is LIG1 and why does it matter in breast cancer?
LIG1 (DNA ligase I) is a gene involved in repairing DNA. When it is lost in TP53-mutant triple-negative breast cancer, the tumor becomes resistant to platinum chemotherapy but becomes vulnerable to specific drug combinations.
Which drugs were found to be effective?
According to the Baylor study, the combination of olaparib (a PARP inhibitor) and ceralasertib (an ATR inhibitor) showed significant effectiveness in reducing tumor growth.
Is this treatment currently available for all TNBC patients?
No. The study identifies LIG1 loss as a specific biomarker. The combination therapy is intended for a subset of patients with TP53 mutations and low LIG1 levels.
Want to stay updated on the latest breakthroughs in cancer research? Subscribe to our medical newsletter or leave a comment below to discuss how precision medicine is changing oncology.
Worth a look